Get started
Author

Takahiro Jikoh

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
2017 · Toshihiko Doi, Kohei Shitara, et al. · The Lancet Oncology · 517
The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
2019 · Takashi Nakada, Kiyoshi Sugihara, et al. · Chemical and Pharmaceutical Bulletin · 460
PDF
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
2019 · Kenji Tamura, Junji Tsurutani, et al. · The Lancet Oncology · 361
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
2020 · Junji Tsurutani, Hiroji Iwata, et al. · Cancer Discovery · 359
Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study
2022 · Ian Krop, Dejan Juric, et al. · Cancer Research · 51
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis
2021 · Mikiko Suzuki, Shigehiro Yagishita, et al. · Clinical Cancer Research · 41
FGF-2-Responsive and Spinal Cord-Resident Cells Improve Locomotor Function after Spinal Cord Injury
2010 · Masaki Kasai, Takahiro Jikoh, et al. · Journal of Neurotrauma · 33
OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer
2018 · J. Tsurutani, H. Park, et al. · Journal of Thoracic Oncology · 27
PDF
Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.
2017 · Toshihiko Doi, Hiroji Iwata, et al. · Journal of Clinical Oncology · 25
Phase I study of Efatutazone, an oral PPARγ agonist, in patients with metastatic solid tumors.
2014 · Haruyasu Murakami, Akira Ono, et al. · PubMed · 21
Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy
2023 · Shigehiro Yagishita, Tadaaki Nishikawa, et al. · Clinical Cancer Research · 18
LBA4 Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial
2021 · A. Bardia, D. Juric, et al. · Annals of Oncology · 17
Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation
2016 · K. Tamura, K. Shitara, et al. · Annals of Oncology · 13
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
2018 · Tomoya Yokota, Johanna Bendell, et al. · British Journal of Cancer · 11
PDF
Abstract PD3-07: Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers
2018 · S Modi, J Tsurutani, et al. · Cancer Research · 10
A call for global harmonization of phase I oncology trials: Results from two parallel, first-in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid tumors conducted in the United States and Japan.
2017 · Tomoya Yokota, Johanna C. Bendell, et al. · Journal of Clinical Oncology · 6
A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.
2018 · Jose Baselga, Kenji Tamura, et al. · Journal of Clinical Oncology · 5
Abstract A145: DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a potent anti-tumor efficacy with differentiation from T-DM1 in preclinical studies
2015 · Yusuke Ogitani, Junko Yamaguchi, et al. · Molecular Cancer Therapeutics · 3
ADCs on the Market and in Clinical Development
2019 · Yuki Abe, Kiyoshi Sugihara, et al. · Springer eBooks · 2
Phase I Clinical Trial of Ds-7423, an Oral Pi3K/Mtor Dual Inhibitor, in Japanese Patients with Advanced Solid Tumors
2014 · T. Yokota, T. Tsushima, et al. · Annals of Oncology · 2
Supplementary Figure 2 from Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy
2025 · Shigehiro Yagishita, Tadaaki Nishikawa, et al.
Supplementary Figure 1 from Co-Clinical Study of [fam-] Trastuzumab Deruxtecan (DS8201a) in Patient-Derived Xenograft Models of Uterine Carcinosarcoma and Its Association with Clinical Efficacy
2025 · Shigehiro Yagishita, Tadaaki Nishikawa, et al.
PDF
Data from Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy
2024 · Shigehiro Yagishita, Tadaaki Nishikawa, et al.
Supplementary Figure 1 from Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy
2024 · Shigehiro Yagishita, Tadaaki Nishikawa, et al.
Supplementary Figure 2 from Co-clinical study of [fam-] trastuzumab deruxtecan (DS8201a) in patient-derived xenograft models of uterine carcinosarcoma and its association with clinical efficacy
2024 · Shigehiro Yagishita, Tadaaki Nishikawa, et al.
Works count: 45
Citation count: 1,982
H-index: 13
I10-index: 15
Year
Topic
Type